Please login to the form below

Not currently logged in
Email:
Password:

Boston Biomedical appoints commercial head

Patricia Andrews joins from Incyte Corporation

Boston Biomedical has named Pfizer veteran Patricia Andrews as chief commercial officer.

Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic colorectal cancer.

She previously spent 17 years at Pfizer, rising to VP and general manager of US oncology, before joining from oncology/inflammation-focused Incyte Corporation where she served as executive VP and chief commercial officer.

At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.

Andrews is expected to perform a similar role at Boston, which has so far been focused on research.

"I am very excited about this opportunity and look forward to building a world-class commercial oncology team at Boston Biomedical," she said.

21st November 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics